
To own GE HealthCare Technologies you need to believe the push into AI powered imaging, software, and recurring service contracts can gradually improve the business mix while earnings remain supported by the large installed base. The recent beat in basic and diluted EPS from continuing operations keeps that margin story intact in the near term.
The most important short term swing factor still looks like execution on cost control and supply chain, especially in Patient Care Solutions, while keeping tariff and legal related noise contained. Taha Kass Hout’s planned exit as Chief Science and Technology Officer creates some leadership turnover in AI, but on its own does not materially change that risk reward balance right now.
The Allia Celeo launch ties directly into that catalyst. It extends GE HealthCare Technologies deeper into higher value interventional imaging rooms where hardware, software, and service contracts work together. That supports the effort to lean the portfolio toward systems that typically demand advanced visualization and digital tools, which can feed recurring revenue streams over time.
This platform also concentrates execution risk. Allia Celeo depends on smooth room integration, reliable AI image quality, and uptime supported by OnWatch Predict remote monitoring. Any stumble there or delays in regulatory clearance in the United States could slow the shift toward richer margins and leave the group more exposed to existing issues in Patient Care Solutions and tariff related cost pressure.
GE HealthCare Technologies' current analyst script assumes revenue grows at 4.9% a year and reaches US$25.0b with earnings of US$2.8b by 2029. That path starts from earnings today of US$2.2b and implies an earnings increase of US$0.6b over the period.
Uncover why GE HealthCare Technologies' fair value indicates a 5% potential upside to its current price that may not last much longer.
One alternate view puts much more weight on product momentum than on leadership churn at GE HealthCare Technologies. The most optimistic analysts were already working off revenue of about US$25.6b and earnings of roughly US$3.0b by 2029. You can now ask whether the new AI launches and the CTO exit shift that curve up or down, and then compare several viewpoints before deciding what makes sense to you.
Explore 3 other GE HealthCare Technologies fair value estimates, including one that suggests as much as 106% potential upside from the current price.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis.
If the GE HealthCare Technologies story has you thinking about where else AI, strong balance sheets, or steady income streams might matter, a broader sweep of the market can sharpen your watchlist. The Simply Wall St Screener can help you quickly filter for very different types of opportunities that might suit your own risk tolerance and time horizon.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com